Canbex Therapeutics Limited

Canbex Therapeutics is dedicated to the development of novel compounds for the treatment of spasticity in multiple sclerosis (MS) and potentially other disorders.

Supported by the US National Multiple Sclerosis Society, the Wellcome Trust and VC investors, Canbex is currently advancing its lead candidate, VSN16R, in preparation for clinical trials which are anticipated to begin in 2013.

Click here to download the Canbex Fact Sheet

There is a clear medical need for spasticity treatments with improved tolerability, and VSN16R is being developed to meet that need. Spasticity is among the most painful, damaging and debilitating symptoms of MS. Spasticity is characterized by sudden and uncontrollable movements of limb and torso musculature. Current drug treatments have a high level of undesirable side effects, and many patients are treated with palliative measures alone, such as pads or slings, or confined to a wheelchair.

VSN16R is a novel orally active small molecule that has been shown to be substantially more tolerable than existing anti-spastic agents. VSN16R does not cause the flaccidity ('rag doll effect'), sedation or other side-effects that are major disadvantages of baclofen, a widely used anti-spastic, and other agents.

VSN16R is currently in IND/CTA-enabling preclinical development, and results to date have confirmed the excellent safety and tolerability of the compound.

About Canbex Therapeutics Ltd.

Canbex is a capital efficient, single-asset, low-burn vehicle that was established solely to develop the VSN compound series for sale or partnering.

In addition to its pioneering scientific founders, Canbex has assembled a skilled and focused management team. Development activities are carried out through professionally managed outsourcing to well-established CROs and CMOs, with business infrastructure and project support provided by Canbex shareholder UCL Business Ltd.

Canbex is supported by two of the world's leading medical foundations, the US National Multiple Sclerosis Society through its 'Fast Forward' commercialisation arm, and the UK's Wellcome Trust via a Translation Award.


Canbex Therapeutics Ltd.
The Network Building
97 Tottenham Court Road
W1T 4TP

T. 020 7679 9000
E. enquiries@canbex.co.uk

Company number: 05073720